On ECHEMI
Home > Drugs > Inflammation-related glaucoma
Inflammation-related glaucoma
Inflammation-related glaucoma is a secondary glaucoma that often combines angle-closure and open-angle components. The mechanism of inflammation-related secondary open-angle glaucoma may be caused by trabecular meshwork edema, corneal endothelial cell dysfunction, uveal fibrinous exudates and inflammatory cells blocking the trabecular meshwork, and prostaglandin mediation, as well as inflammation destroying the blood-aqueous barrier to produce serous aqueous humor, causing aqueous humor drainage obstruction. Inflammation-related secondary angle-closure glaucoma may be caused by the destruction of the blood-aqueous barrier, the increase of protein and fibrinous exudates in the aqueous humor, and the deposition in the eye to form posterior iris synechiae. If not treated in time, it may eventually form iris bulging and secondary angle closure. At the same time, peripheral iris tissue edema and inflammatory debris at the iridocorneal angle are prone to form peripheral anterior synechia (PAS) after organization. Gonioscopy shows that the PAS left over from inflammation has different shapes and heights, which can be distinguished from primary angle-closure glaucoma. During eye inflammation, ciliary body swelling and anterior rotation can cause uveal exudation, which in turn causes the iridocorneal angle to become shallow and closed. Inflammatory large KP blocks the iridocorneal angle, and severe posterior uveitis can manifest as secondary extensive exudative retinal detachment and anterior displacement of the irido-lens septum, which can also lead to angle-closure glaucoma.
  • Site of disease:

    Eye
  • Infectious :

    Not contagious
  • Frequent population:

    All groups
  • Related symptoms:

    Segmental iris atrophy eye pain epileptic tear visual impairment lacrimal cyst
Related Drugs
Mingmu Dihuang Pills
Manufacturer:

Hebei Bianque Pharmaceutical Co., Ltd.

Mingmu Dihuang Pills
Manufacturer:

Hebei Bianque Pharmaceutical Co., Ltd.

Methazolamide Tablets
Indication: It is used as an adjuvant treatment for patients with primary open-angle glaucoma, angle-closure glaucoma and some secondary glaucoma whose intraocular pressure is not well controlled by topical anti-glaucoma drugs. Because this product has less effect on acid-base balance while lowering intraocular pressure, it is better than acetazolamide for patients with severe obstructive pulmonary disease. Methazolamide has less effect on urinary citrate secretion than acetazolamide, so it is recommended for patients who need oral carbonic anhydrase inhibitor treatment but are prone to kidney stone formation.
Manufacturer:

Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.